Open Access
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1062 - 1065
Section Les anticorps armés
Published online 06 January 2020
  1. Mathé G, Loc Tran Ba, Bernard J , Effet sur la leucémie 1210 de la souris d’une combinaison par diazotation d’améthopterine et de gammaglobulines de hamsters porteurs de cette leucémie par hétérogreffe. CR Hebd Seances Acad Sci. 1958;246:1626–1628. [Google Scholar]
  2. Srivastava SC, Buraggi GL , NATO Advanced study institute on radiolabeled monoclonal antibodies for imaging and therapy–potential, problems, and prospects. Int J Biol Markers. 1987;2:43–48. [CrossRef] [PubMed] [Google Scholar]
  3. Robbins RJ, Schlumberger MJ , The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46(suppl 1):S28–S37. [Google Scholar]
  4. Grünwald F, Ezziddin S , 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2010;40:153–163. [CrossRef] [PubMed] [Google Scholar]
  5. Goldenberg DM , Current status of cancer imaging with radiolabeled antibodies. J Cancer Res Clin Oncol. 1987;113:203–208. [CrossRef] [PubMed] [Google Scholar]
  6. Mach JP, Carrel S, Forni M, et al. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med. 1980;303:5–10. [Google Scholar]
  7. Larson SM, Carrasquillo JA, Cheung N-KV, et al. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–360. [Google Scholar]
  8. Goldsmith SJ , Radioimmunotherapy of lymphoma: Bexxar and Zevalin®. Semin Nucl Med. 2010;40:122–135. [CrossRef] [PubMed] [Google Scholar]
  9. Vallabhajosula S, Nikolopoulou A, Jhanwar YS, et al. Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTAhuJ591 anti-prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm. 2016;9:44–53. [CrossRef] [PubMed] [Google Scholar]
  10. Brans B, Bodei L, Giammarile F, et al. Clinical radionuclide therapy dosimetry: the quest for the Holy Gray. Eur J Nucl Med Mol Imaging. 2007;34:772–786. [PubMed] [Google Scholar]
  11. Strosberg J, Krenning E , 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:1391–1392. [Google Scholar]
  12. von Eyben FE, Roviello G, Kiljunen T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45:496–508. [PubMed] [Google Scholar]
  13. Loktev A, Lindner T, Mier W, et al. A Tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–1429. [CrossRef] [PubMed] [Google Scholar]
  14. Wissing MD, van Leeuwen FWB, van der Pluijm G, et al. Radium-223 chloride: extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 2013;19:5822–5827. [CrossRef] [PubMed] [Google Scholar]
  15. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–1944. [CrossRef] [PubMed] [Google Scholar]
  16. Jurcic JG , Clinical studies with Bismuth-213 and Actinium-225 for hematologic malignancies. Curr Radiopharm. 2018;11:192–199. [CrossRef] [PubMed] [Google Scholar]
  17. Meredith R, Torgue J, Shen S, et al. Dose escalation and dosimetry of first-in-human α-radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 2014;55:1636–1642. [CrossRef] [PubMed] [Google Scholar]
  18. Sgouros G , Alpha-particles for targeted therapy. Adv Drug Deliv Rev. 2008;60:1402–1406. [CrossRef] [PubMed] [Google Scholar]
  19. Batra SK, Jain M, Wittel UA, et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002;13:603–608. [Google Scholar]
  20. Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:170511. [Google Scholar]
  21. Altai M, Membreno R, Cook B, et al. Pretargeted Imaging and therapy. J Nucl Med. 2017;58:1553–1559. [CrossRef] [PubMed] [Google Scholar]
  22. Joubert N, et al. ADC : le grand retour des médicaments couplés aux anticorps. Med Sci (Paris). 2019;35:1034–1042. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Ménager J, Gorin JB, Fichou N , Radio-immunothérapie alpha : principes et intérêts en immunité antitumorale. Med Sci (Paris). 2016;32:362–369. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Mortier L, et al. Une révolution en oncologie, bilan de l’efficacité. Med Sci (Paris). 2019;35:937–945. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  25. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–5164. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.